# YK Bioventures

> YK Bioventures is a VC fund backing Biotechnology and Therapeutics. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 15
- Last investment: Jan 2026
- Lead investor: 13%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/yk-bioventures

YK Bioventures is a venture fund that invests in the biotech industry. YK Bioventures helps scientists and entrepreneurs bring new technologies to patients. YK Bioventures was founded in 20203 and was headquartered in San Francisco, California.

## Contacts

5 contacts available for YK Bioventures. Shizune tracks 1 team members at YK Bioventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/yk-bioventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 9 | 60% |
| Therapeutics | 8 | 53% |
| Medical | 4 | 27% |
| Biopharma | 4 | 27% |
| Life Science | 3 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 33% |
| Series B | 4 | 27% |
| Seed | 1 | 7% |
| Series F | 1 | 7% |
| Funding Round | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gary Yeung | Co-Founder and Co-CIO | 2 | https://shizune.co/investors/profile/gary-yeung |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Think Bioscience | Think Bioscience is reimagining synthetic biology by guiding the design and assembly of better medicines through the use of living systems. | $55M | Series A | Jan 20, 2026 |  |
| Vivere Oncotherapies | Vivere develops targeted cancer therapies that activate the immune system to detect and destroy tumors using engineered bio-platforms. | $10M | Seed | Jan 13, 2026 |  |
| Psivant Therapeutics | Psivant Therapeutics is a biotechnology company that offers drug design, biology research, and development services. | $47.5M | Series A | Dec 10, 2025 |  |
| Triana Biomedicines | Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. | $120M | Series B | Dec 03, 2025 |  |
| Protego Biopharma | Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $130M | Series B | Dec 01, 2025 |  |
| Pelage Pharmaceuticals | Pelage Pharma delivers a clinically tested treatment for both men and women battling the emotional pain or social stigma of hair loss. Its non-invasive, topical small molecule drug platform activates hair follicle stem cells and stimulates robust hair growth. | $120M | Series B | Oct 15, 2025 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M |  | Apr 03, 2025 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M | Series F | Apr 03, 2025 |  |
| Normunity | Normunity is a biotechnology company creating a new class of precision immuno-oncology medicines, called immune normalizers, that target novel mechanisms that free the body’s normal immunity against cancer.Based on an ongoing, interactive academic-biotech alliance with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is targetingnewly-discovered mechanisms of immune disruption in cancer based on proprietary discovery platforms that elucidate the complex interactions between human cancer and the immune system. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer.Normunity is located in Boston, Massachusetts and West Haven, Connecticut. | $75M | Series B | Jan 13, 2025 |  |
| Judo Bio | Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases. By leveraging its innovative receptor targeting approach, Judo Bio is developing a pipeline aimed at benefiting patients with both common and rare diseases. | $75M | Series A | Oct 07, 2024 |  |

10 of 15 investments shown.

## Co-investors
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 7 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 5 deals together
- [Main Street Advisors](https://shizune.co/investors/profile/main-street-advisors-inc) — VC Fund, 3 deals together
- [Regeneron Ventures](https://shizune.co/investors/profile/regeneron-ventures) — VC Fund, 3 deals together
- [Visionary Venture Fund](https://shizune.co/investors/profile/visionary-venture-fund) — VC Fund, 3 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does YK Bioventures invest in?

YK Bioventures invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact YK Bioventures?

Public channels for YK Bioventures include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at YK Bioventures?

The team at YK Bioventures includes Gary Yeung (Co-Founder and Co-CIO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co